AMS Planning, Inc.は北大発認定スタートアップ企業です

AMS Planning, Inc. Advanced Medical Science Planning, Inc.

About us

Cure Better, Innovation

Advanced Medical Science-Planning, Inc (AMS) is a Japanese VC-backed nuclear medicine start-up company seeking to transform Japan’s nuclear industry and provide new business and economic growth opportunities following the March 2011 Fukushima Nuclear Power Station Accident.

Pursuant to our corporate mantra “Cure Better, Innovation,” AMS will deploy nuclear medicine-based Theranostics, which combines both therapeutic and diagnostic capabilities in one dose for cancer treatment, as well as pair Theranostics with artificial intelligence to enhance their effectiveness in terms of Precision Oncology.

In connection with executing our disruptive growth strategy, AMS is presently working in the application process to the Pharmaceutical and Medical Devices Agency (PMDA) on a phased approach to bring the 68Ga-Based PET-Radiopharmaceuticals including 68Ga-PSMA and 68Ga-DOTATOC that are available in Europe and the United States, to Japan. AMS has adopted a unique regulatory approach to obtain marketing approval for the automated synthesizer as a medical device producing the PET-Radiopharmaceuticals, based on our deep understanding of the Act on the Regulation of Radioisotopes and the Medical Care Act, which differs from a common regulatory path among Western countries for radiopharmaceuticals as a drug.

AMS also plans to establish the capability to produce radioisotopes of interest in Japan as part of our overall strategy for Japan and the Asian region. AMS, through its subsidiary Medical Isotope Prime Japan (MIPJ), is also securing long-term, stable supplies of vital medical isotopes such as actinium225 (Ac225) to enable the development of new treatments by Japanese research institutions and hospitals.



AMS team is the right mix of passion and experience from diversified industries, including experts in nuclear medicine, business development, and regulatory affairs.
  • Yuichiro Sugawara, MBA (Representative Director, President and CEO)
    Suga founded AMS in 2019, motivated by minimally invasive therapy and Fukushima Daiichi Accident, which has led him to focus on nuclear medicine. Suga has 20 years of business development experience in TEPCO and other companies with various senior business management roles.
    Suga has a bachelor’s and a master’s degree in engineering from Waseda University and an MBA from the Washington University in Saint Louis, Olin School of Business.
  • Toshihide Kubo (Director and Chief Operating Officer)
    Kubo joined AMS in July 2019 as Director and Chief Operating Officer. Kubo has 30 years of strategic investment and business management experience at Marubeni corporation, including as an outside director of Given Imaging Ltd. (now Medtronic).
    Kubo has a bachelor’s degree in engineering from Keio University.
  • Hiroyuki Okada (Outside Director)
    Okada joined AMS as an outside director in December 2022. Okada joined TEPCO in 1996, where he was involved in the development of Next Generation Nuclear Reactors in the Nuclear Energy Division. He was then transferred to TNP Partners (VC), where he was in charge of hands-on support. With a deep understanding of "large enterprises and small business" and "business company and finance," he has accumulated much experience in strategic planning and implementation, from business composition to service and sales strategy.
    Okada has a B.S. in Materials Science and an M.S. in Nuclear Engineering from the Tokyo Institute of Technology and holds a Chief Nuclear Reactor Engineer license in Japan.
  • Komei Washino, Ph.D. (Chief Technology Officer)
    Washino joined AMS in Dec 2019 as Nuclear Medicine Technical Manager. Washino has 30 years of experience in drug development, research, and commercialization of innovative radiopharmaceuticals. Before AMS, Washino was a Director at Nihon Medi-Physics, held academic appointments as a research professor at Hokkaido University Graduate School of Medicine and visiting researcher at the National Institutes for Quantum and Radiological Science and Technology (QST).
    Dr. Washino received his DVM, Doctor of Veterinary Medicine, and Ph.D. from the Faculty of Veterinary Medicine, Hokkaido University.
  • Noriake Okamoto (Nuclear Medicine Academic Office Manager)
    Okamoto joined AMS in Feb 2019 as Nuclear Medicine Academic Office Manager. Okamoto has spent 40 years in commercial and business development roles in companies in the nuclear medicine sector, beginning his career with Daiichi-RI Pharma (Now Fujifilm Toyama Kagaku) in 1975, including as General Manager for Bristol-Myers Squibb and Dupont. Okamoto also held an academic appointment as a lecturer at CHIBA INSTITUTE OF SCIENCE, Faculty of Risk and Crisis Management, Department of Health and Medical Sciences.
    Okamoto holds a pharmacist license in Japan, a bachelor of pharmacy from Shizuoka Prefectural college of Pharmacy and was a research fellow at Pharmaceutical Science, Tokyo University.
  • Meizo Kusaka, Ph.D. (Regulatory Office Manager)
    Kusaka joined AMS in May 2020 as Regulatory Office Manager. Kusaka has 40 years of experience in regulatory and clinical affairs, beginning his career with Zeria Pharmaceutical KK in 1978, including managerial roles at Marion Merrell Dow K.K. (Now Aventis Pharma Co.), Bristol-Myers Squibb KK, St.Jude Medical Company, and ConvaTec Japan KK. Kusaka also holds an academic appointment as a lecturer at Kyoto Tachibana University, Faculty of Nursing.
    Kusaka received a bachelor of pharmacy from Nihon University, M.S., Pharmacy from Kitasato University, and Ph.D., Pharmacy from Hoshi University. Kusaka holds a pharmacist's license in Japan.
  • Keiichi Hirano (Chief Engineer)
    Hirano joined AMS in Sep 2023 as Chief Engineer. Hirano has 40 years of experience in the production of radiopharmaceuticals (GMP), which has been distributed all over Japan in a safe, stable, and reliable manner for many years; the development of several types of Radiopharmaceutical Synthesizer for the production of radiopharmaceuticals labeled with Ga67/I123/F18 and more recently At211, where he has collaborated with significant universities and hospitals dedicated to nuclear medicine in Japan.
    Before AMS, Hirano worked for Nihon Medi-Physics and its subsidiary.


Name of company
Advanced Medical Science-Planning, Inc
Paid-In Capital
123,990,500 JPY
Description of business
Production, import, development and sales of
radio-isotopes and medical devices
5-6-9-303, Shirokanedai, Minato-Ku,
Tokyo, 108-0071, Japan
Email Address